Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6

Fig. 1

UBE2D1 was upregulated in HCC and predicted a poor prognosis of HCC patients. a The transcript level of UBE2D1 were determined by real-time PCR in HCC and paired adjacent nontumor tissues in HCC Cohort (n = 108). β-actin was used as internal control. b Relative expression of UBE2D1 measured by quantitative PCR in precancerous lesions and paired nontumor tissues without lesions(n = 9) and HCC tissues(n = 108). c Relative transcript level of UBE2D1 measured by quantitative PCR in normal(n = 41) and hepatitis liver tissues(n = 22) compared with in HCC tissues. d Representative western blotting image of UBE2D1 in tumor(T) and corresponding nontumor tissues(N)(n = 19). 12/19, upregulated in tumor; 3/19, downregulated in tumor; 4/19, no differences between tumor and nontumor. The value of blotting images was showed in the right panel. e Kaplan-Meier analyses of the correlations between relative intensity of UBE2D1 in GSE14520 and overall survival of HCC patients. The median intensity was used as the cutoff for low and high group. **p < 0.01, ***p < 0.001

Back to article page